Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pyxis Oncology Inc PYXS

Healthcare Biotechnology
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma... see more

Recent & Breaking News (NDAQ:PYXS)

Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update

GlobeNewswire November 1, 2022

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 30, 2022

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update

GlobeNewswire August 15, 2022

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 12, 2022

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

GlobeNewswire June 28, 2022

Pyxis Oncology Announces Presentations at Upcoming Investor Conferences

GlobeNewswire May 19, 2022

Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

GlobeNewswire May 13, 2022

Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference

GlobeNewswire April 27, 2022

Pyxis Oncology Announces Leadership Changes

GlobeNewswire April 13, 2022

Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire April 8, 2022

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

PR Newswire March 29, 2022

Pyxis Oncology Provides Corporate and Financial Update

GlobeNewswire March 29, 2022

Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022

GlobeNewswire March 22, 2022

Pyxis to be Added to Russell 2000® Index

GlobeNewswire December 15, 2021

Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer

GlobeNewswire December 9, 2021

Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update

GlobeNewswire November 15, 2021

Pyxis Oncology to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 10, 2021